A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...

New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approxima ...

Retention has always been a central concern in long-term studies, but obesity trials present a particular challenge. For those assigned to receive the drug candidate in question, the effects are ...

Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. Click ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided ...

Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 10:00 AM ESTCompany ParticipantsNadim Ahmed - ...

The trial enrolled 274 adults evenly assigned to receive subcutaneous Taltz alone or combined with Zepbound.

US FDA accepts Roche’s NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer: Basel Saturday, February 21, 2026, 11:00 Hrs [IST] Roche announced that the Unit ...